6.825USD+3.10%Mkt Cap: 676.35M USDP/E: —Last update: 2026-05-26
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrop…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap676.35M USD
Enterprise Value279.91M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-174.32M USD
Revenue/Share—
Last Price6.825 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.37
PEG—
EV/EBITDA-1.44
EV/Revenue—
P/S—
P/B1.71
EPS (TTM)-1.92
EPS (Forward)-1.93
52W Range
2.72567% of range8.866
52W High8.866 USD
52W Low2.725 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-96.84%
ROA-74.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-156.29M USD
CapEx (TTM)1.15M USD
FCF Margin—
FCF Yield-16.41%
Net Debt-360.01M USD
Net Debt/EBITDA1.85
Balance Sheet
Debt/Equity0.12
Current Ratio13.10
Quick Ratio12.57
Book Value/Sh3.802 USD
Cash/Share3.867 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 28, 2022
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)17.00 USD
Target Range11.00 USD – 26.00 USD
# Analysts13
Ownership
Shares Out.98.45M
Float53.74M
Insiders0.82%
Institutions101.69%
Short Interest
Short Ratio9.1d
Short % Float10.30%
Short % Out.8.95%
Shares Short8.81M
Short (prev mo.)10.05M
Technical
SMA 507.474 (-8.7%)
SMA 2006.174 (+10.5%)
Beta2.47
S&P 52W Chg28.31%
Avg Vol (30d)1.08M
Avg Vol (10d)1.27M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—